FindTrial
Sign In

Clinical Study of Chinese Herbal Drugs with the Effects of Reinforcing Qi and Activating Blood for Prevention Restenosis after Vertebral Artery Initial Segment Stenting

Clinical Study of Chinese Herbal Drugs with the Effects of Reinforcing Qi and Activating Blood for Prevention Restenosis after Vertebral Artery Initial Segment Stenting

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005542
Enrollment
Unknown
Registered
2014-11-04
Start date
2014-10-27
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic cerebral vascular disease

Interventions

test group:Naoxintong capsule
control group :placebo

Sponsors

Xiyuan Hospital of China Academy of Chinese Medicine Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) After vertebral artery initial segment stenting, accord with Qi deficiency and blood stasis; 2) Age 30-80, no pregnancy plan in 6 months; 3) Good compliance and cooperation; 4) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with severe heart, liver,kidney disease, blood coagulation dysfunction or malignant tumor; 2) Pregnant or lactating women; 3) Bad compliance and cooperation, refused to sign the consent.

Design outcomes

Primary

MeasureTime frame
the rate of restenosis;—

Secondary

MeasureTime frame
The incidence of cerebral ischemic symptoms;—

Countries

China

Contacts

Public ContactTONG Chenguang
xytcg@sina.com+86 010 62835382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026